Enlansibumab with chemoradiation for advanced cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new drug called enlansibumab (an immunotherapy that helps your immune system fight cancer) given with standard chemotherapy and radiation for locally advanced cervical cancer. It aims to see if adding this drug improves outcomes for patients whose cancer has spread to nearby lymph nodes but not to distant organs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 70.
- You have a type of cervical cancer called squamous cell carcinoma, adenocarcinoma, or adenosquamous cell carcinoma.
- Your cancer is stage IIB to IVA (locally advanced) and has spread to lymph nodes in the pelvis or abdomen.
- You have not had any previous treatment for your cancer (except a biopsy).
- You are in generally good health (able to care for yourself) and have adequate organ function.
- You have a tumor sample (biopsy) that can be tested for certain markers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemoradiation for locally advanced cervical cancer caused by HPV. It may be an option for women with stage 3-4A disease or positive lymph nodes who have not had immunotherapy before.
This trial tests a new drug called Enlonstobart, which helps the immune system fight cancer, given with standard chemotherapy and radiation for patients with locally advanced cervical cancer. The goal is to see if this combination is effective and safe.
This study tests whether adding a new immunotherapy drug, envafolimab, to standard chemotherapy and radiation can improve outcomes for patients with locally advanced cervical cancer. You may receive the experimental drug along with your usual treatment, which could help your body fight the cancer more effectively.
This trial tests a new drug (QL1706) combined with chemotherapy before the usual radiation therapy for locally advanced cervical cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests if giving the immunotherapy drug pembrolizumab before and after standard chemoradiation works better than the standard approach for people with high-risk cervical cancer that has spread locally.
This trial tests a combination of new immunotherapy drugs (LB1410 and maybe LB4330) with lenvatinib (a targeted therapy) in patients with advanced cervical cancer that came back or spread. The goal is to see if this combo shrinks tumors or slows the cancer better than standard options.
Hear when a new LOCALLY ADVANCED CERVICAL CANCERS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.